Lexeo Therapeutics, Inc. LXEO 深 滬
已收盤 04-02 16:00:00 美东时间
5.72
+0.050
+0.88%
華盛通- 最 高5.83
- 今 開5.51
- 成交量 62.58万股
- 最 低 5.48
- 昨 收 5.67
- 總市值 4.24亿
- 52周最高 10.99
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 1.965
- 委 比 56.93%
- 總股本 7408.71万
- 歷史最高 22.33
- 量 比 0.62
- 振 幅 6.17%
- 歷史最低 1.45
- 每 手 1
- 風險率 2.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lexeo Therapeutics Q4 EPS $(0.27) Beats $(0.34) Estimate
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.34) by 21.28 percent. This is a 65.38 percent increase over losses of $(0.78) per share
03-31 04:30
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.
01-13 21:50
Lexeo Therapeutics Announces Research Collaboration With Johnson & Johnson To Explore Targeted Cardiac Delivery Of AAV Gene Therapy
Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella heart pumps Agreement will
01-08 20:05
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Lexeo Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $25 price target.
Lexeo Therapeutics shares are trading higher after Raymond James initiated cove...
2025-12-18 22:13
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.
2025-12-11 20:19
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Lexeo Therapeutics will host a virtual event on December 9 at 3 PM ET during the 22nd Global Cardiovascular Clinical Trialists Forum. The session, titled "A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy," will feature Dr. Victoria Parikh, an expert in this condition. Investors and analysts can register via Lexeo’s website, with a replay available post-event. Lexeo is a clinical-stage genetic ...
2025-12-04 13:00
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
